Lange T, Ernst T, Gruber FX, Maier J, Cross M, Müller MC, Niederwieser D, Hochhaus A, Pfirrmann M. The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica [Internet]. 2013Apr.30 [cited 2026Nov.14];98(5):714-7. Available from: https://haematologica.org/article/view/6658